AnodyneWiki

Bilastine

Bilastine
Bilastine
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass463.60 g/mol [1]
Predicted LogP2.3 [1]
Structural Identifiers
[]
Molecular formulaC28H37N3O3
IUPAC name2-[4-[2-[4-[1-(2-ethoxyethyl)benzimidazol-2-yl]piperidin-1-yl]ethyl]phenyl]-2-methylpropanoic acid
SMILESCCOCCN1C2=CC=CC=C2N=C1C3CCN(CC3)CCC4=CC=C(C=C4)C(C)(C)C(=O)O
InChIInChI=1S/C28H37N3O3/c1-4-34-20-19-31-25-8-6-5-7-24(25)29-26(31)22-14-17-30(18-15-22)16-13-21-9-11-23(12-10-21)28(2,3)27(32)33/h5-12,22H,4,13-20H2,1-3H3,(H,32,33)
InChIKeyACCMWZWAEFYUGZ-UHFFFAOYSA-N
CAS number202189-78-4
UNIIPA1123N395
PubChem CID185460
Pharmacokinetics[]
Onset1 hour (Allertine)
Elimination half-life14.5 hours
Duration of action24 hours (Allertine)
MetabolismNot significantly metabolised
Excretion95% in urine and faeces
Routes of administrationBy mouth

Bilastine (also known as Ilaxten, Bilastina, Bilastinum, R06ax29, Bilaxten, Gtpl11579, Bs-15792, Bilasten, Bilatex or Bilastine?) is a substance of the phenethylpiperidine class.

Chemistry

 []

Bilastine is achiral.

Bilastine matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

Bilastine is a selective histamine H1 receptor antagonist (Ki = 64nM). During allergic response mast cells undergo degranulation which releases histamine and other subastances. By binding to and preventing activation of the H1 receptor, bilastine reduces the development of allergic symptoms due to the release of histamine from mast cells. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target3

Subjective effects []

0xea / Bilastine []
Routes:
  • Oral (20mg)
Notes:
  • seamed too improve allergy symptoms

 []

  • Australia: Bilastine is a S4 / Schedule 3; Schedule 2; Appendix H, clause 1.[3]
  • Canada: Bilastine is Prescription only.[4]
  • New Zealand: Bilastine is a S2 (Pharmacy Only).[5]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 185460, Bilastine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/185460
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Bilastine. UNII: PA1123N395. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/PA1123N395
  3. Therapeutic Goods (Poisons Standard— June 2025) Instrument 2025. Therapeutic Goods Administration (TGA). May 2025. https://www.legislation.gov.au/F2025L00599/asmade/2025-05-28/text/original/pdf
  4. Health Canada New Drug Authorizations: 2016 Highlights. Health Canada. 14 March 2017. https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-canada-new-drug-authorizations-2016-highlights.html
  5. bilastine classification. (mcc). https://medsafe.govt.nz/profs/class/classintro.asp

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 13:51:31
drugspromissing (no DrugsPRO reagent data)2026-11-20 13:51:27
erowidmissing (no Erowid substance of that name)2026-11-20 13:51:27
gsrsok2026-11-20 13:51:27
hmdbmissing (hmdb.ca refused automated access to HMDB0240232)2026-11-20 13:51:27
keggok2026-11-20 13:51:28
pubchemok2026-11-20 13:51:27
redditmissing (no r/tripreports posts mention it)2026-11-20 13:51:27
sidermissing (not in SIDER)2026-11-20 13:51:27
structureok2026-11-20 13:51:27
wikipediaok2026-11-20 13:51:27